Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

47.62 -1.35 (-2.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics

< Previous 1 2 3 4 5 6 7 Next >
Expert Ratings for Corcept Therapeutics
Via Benzinga
Corcept Therapeutics Inc. (NASDAQ: CORT) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
Why Corcept Therapeutics Stock Popped Today
Corcept Therapeutics Incorporated (NASDAQ: CORT) shares surged Thursday following a second-quarter earnings beat. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90... 
Via Benzinga
Earnings Preview For Corcept Therapeutics
Via Benzinga
Analyst Expectations for Corcept Therapeutics's Future
Via Benzinga
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics's Return On Capital Employed Overview
Via Benzinga
Analyst Ratings for Corcept Therapeutics
Via Benzinga
Analyst Expectations for Corcept Therapeutics's Future
Via Benzinga
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2023
Via Benzinga
Corcept Therapeutics Announces Final Results of Tender Offer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Short Volatility Alert: Corcept Therapeutics
On Tuesday, shares of Corcept Therapeutics (NASDAQ: CORT) experienced volatile short activity. After the activity, the stock price went up +1.66% to $22.02. The overall sentiment for CORT has been... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
Via Benzinga
Corcept Therapeutics Announces Preliminary Results of Tender Offer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Initiates CATALYST Clinical Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
Via Benzinga
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
From Corcept Therapeutics Incorporated
Via GlobeNewswire
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.